Skip to main content

Artelo Biosciences, Inc.

corporate_fare Company Profile

Artelo Biosciences, Inc.

ARTL·NASDAQ·Life Sciences·CIK 0001621221

The company, incorporated in Nevada on May 2, 2011, and based in San Diego, California, is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing treatments that target lipid-signaling modulation pathways, including the endocannabinoid system. The company's product pipeline utilizes scientific methodologies to develop pharmaceuticals for patients with unmet healthcare needs. Its primary program involves ART27.13, a novel, benzimidazole dual cannabinoid (CB) agonist that targets both the CB1 and CB2 peripheral receptors. This synthetic small molecule, a G protein-coupled receptor (GPCR), was initially developed by AstraZeneca plc. The company is developing ART27.13 as a potential treatment for cancer-related anorexia and it is currently in a Phase 1b/2a trial called the Cancer Appetite Recovery Study (CAReS). An interim analysis of the ongoing Phase 2a CAReS trial showed that patients with cancer anorexia receiving ART27.13 had a mean weight gain of over 6% compared to a 5% loss in the placebo group, while maintaining a safety profile similar to Phase 1b, even at doses up to twice the previous maximum. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome. The company's second program, ART26.12, is a small molecule and the lead product candidate from its chemical library of inhibitors of fatty acid binding proteins, specifically Fatty Acid Binding Protein 5 (FABP5). The company received U.S. Food & Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for ART26.12 in July 2024 and has completed enrollment for a Phase 1 clinical trial in healthy subjects. This trial supports the development of ART26.12 as an agent intended to treat chemotherapy-induced peripheral neuropathy (CIPN).

Artelo Biosciences, Inc. (NASDAQ:ARTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for ARTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ARTL spans 10-Q, 8-K, DEFA14A, PRER14A.

Recent high-impact activity:

  • Artelo 10-Q: $4.4M Cash, Going Concern Doubt, $8.8M Nine-Month Cash Burn
  • Artelo Flags Nasdaq $5M MVLS Delisting Risk, Weighs More Dilutive Financing
  • Artelo Files Patent for ART27.13 Obesity Combo; Stock Surges 194%
  • Artelo's ART27.13 Matches Semaglutide Weight Loss, Doubles It in Combo
  • Artelo Biosciences Executes 1-for-9 Reverse Split to Regain Nasdaq Compliance

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$12.88M
Diluted EPS
-$12.52
Op. Cash Flow
-$8.52M
Operating Income
-$11.4M
Cash & Equivalents
$600K
Debt / Equity
0.00×
Shares Outstanding
2.02M sh
Source: 10-K · filed 2026-02-24 · accession 0001640334-26-000368

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 27,721 shares in ARTL as of the October 30, 2026 settlement, a 20.2% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 48.3% of ARTL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)27,721 shares as of October 30, 2026
Change vs prior period▼ 20.2%
Days to cover1.00 at avg daily volume of 38,625
Daily short volume (FINRA facilities)48.3% of 33,482 shares on November 20, 2026
5-day average short volume37.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for ARTL, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.

1 recent capital raiseATM programreverse split

New At-The-Market Offering Launched · Massive Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$1.39
52-week range · as of 2026-11-12 $1.39 – $179.19
Market cap
$1.3M
Volume
52K (1.4× avg)
3-mo avg 37.2K
Live data · 2026-11-21 17:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARTL - Latest Insights

ARTL
Nov 12, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.24
Real-time Price: $1.39 info
Change: -$0.850 (-38%) info
Market Cap: $1.303M info
ARTL
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.19
Real-time Price: $1.39 info
Change: -$1.80 (-56%) info
Market Cap: $1.303M info
ARTL
Sep 23, 2026, 1:46 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $1.39 info
Change: -$6.45 (-82%) info
Market Cap: $1.303M info
ARTL
Sep 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.02
Real-time Price: $1.39 info
Change: -$3.63 (-72%) info
Market Cap: $1.303M info
ARTL
Aug 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.658
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Aug 27, 2026, 8:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.6899
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Aug 20, 2026, 8:52 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7078
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Aug 17, 2026, 8:52 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7698
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Aug 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7071
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Aug 12, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.740
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Aug 10, 2026, 8:47 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.751
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jul 17, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jul 16, 2026, 8:48 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jul 13, 2026, 9:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jul 02, 2026, 4:05 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $1.12
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jul 01, 2026, 8:42 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jun 29, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jun 22, 2026, 4:05 PM EDT
Filing Type: PRER14A
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jun 10, 2026, 7:38 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.31
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
ARTL
Jun 05, 2026, 4:06 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $1.38
Real-time Price: $1.39 info
Change: Reverse Stock Split info
Market Cap: $1.303M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets